SRR8518181
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- CHOLESTEROL_HOMEOSTASIS+0.370
- TGF_BETA_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.360
- ADIPOGENESIS+0.350
- XENOBIOTIC_METABOLISM+0.340
- ANGIOGENESIS+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- FATTY_ACID_METABOLISM+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.380
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.260
- WNT_BETA_CATENIN_SIGNALING-0.260
- ALLOGRAFT_REJECTION-0.250
- KRAS_SIGNALING_DN-0.240
- MYC_TARGETS_V2-0.210
- APICAL_SURFACE-0.180
- MITOTIC_SPINDLE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518325 | — | F | 0.910 |
| 2 | SRR8518315 | — | F | 0.907 |
| 3 | TCGA-73-4659-01A-01R-1206-07 | — | cohortA3 | 0.842 |
| 4 | 20060030.TNBC | — | F | 0.840 |
| 5 | SRR8518414 | — | C | 0.835 |
| 6 | BSR_06_0059_A2_S99 | — | F | 0.828 |
| 7 | TCGA-LL-A740-01A-21R-A32P-07 | — | F | 0.826 |
| 8 | TCGA-AQ-A0Y5-01A-11R-A14M-07 | — | C | 0.814 |
| 9 | TCGA-CN-4726-01A-01R-1436-07 | — | — | 0.813 |
| 10 | SRR8613755 | — | F | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |